Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.59 |
| ▸ | ACE | P12821 | 7/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.56 |
| ▸ | FPR2 | P25090 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CPA1 | P15085 | 2/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6427435 | 1.00 | MME (0.59) | MMEACENPSR1NAALAD2FPR2 | |
| SCHEMBL10504767 | 0.84 | ITGB3 (0.65) | MMEACENPSR1NAALAD2ECE1 | |
| SCHEMBL6316065 | 0.84 | MME (0.61) | MMEACENPSR1NAALAD2FPR2 | |
| SCHEMBL1477208 | 0.84 | ACE (0.62) | MMEACENPSR1NAALAD2ECE1 | |
| SCHEMBL4144668 | 0.84 | ITGB3 (0.65) | MMEACENPSR1NAALAD2ECE1 | |
| SCHEMBL6316057 | 0.84 | FPR2 (0.61) | MMEACENPSR1NAALAD2FPR2 | |
| SCHEMBL4144665 | 0.84 | ITGB3 (0.65) | MMEACENPSR1NAALAD2ECE1 | |
| SCHEMBL14503222 | 0.84 | ACE (0.62) | MMEACENPSR1NAALAD2ECE1 | |
| SCHEMBL21777173 | 0.84 | MME (0.61) | MMEACENPSR1NAALAD2FPR2 | |
| SCHEMBL28593577 | 0.84 | ACE (0.62) | MMEACENPSR1NAALAD2ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200164075-A1 | SMALL MOLECULE INHIBITORS FOR EARLY DIAGNOSIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN CANCERS AND NEURODEGENERATIVE DISEASES | Indian Institute of Technology Indore (IN) | 2020-05-28 | — | — | US | disclosed |
| EP-1212056-B1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | US GOV HEALTH & HUMAN SERV (US) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200164075-A1 | SMALL MOLECULE INHIBITORS FOR EARLY DIAGNOSIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN CANCERS AND NEURODEGENERATIVE DISEASES | PSMA2, PSMA1, PSMA6 | MME 1431/4885ACE 1560/4885NPSR1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.